RU2010101093A - Способы диагностики и лечения рака - Google Patents

Способы диагностики и лечения рака Download PDF

Info

Publication number
RU2010101093A
RU2010101093A RU2010101093/10A RU2010101093A RU2010101093A RU 2010101093 A RU2010101093 A RU 2010101093A RU 2010101093/10 A RU2010101093/10 A RU 2010101093/10A RU 2010101093 A RU2010101093 A RU 2010101093A RU 2010101093 A RU2010101093 A RU 2010101093A
Authority
RU
Russia
Prior art keywords
subject
rrm1
cancer
expression
level
Prior art date
Application number
RU2010101093/10A
Other languages
English (en)
Russian (ru)
Inventor
Джерольд БЕПЛЕР (US)
Джерольд БЕПЛЕР
Original Assignee
Юниверсити Оф Саут Флорида (Us)
Юниверсити Оф Саут Флорида
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юниверсити Оф Саут Флорида (Us), Юниверсити Оф Саут Флорида filed Critical Юниверсити Оф Саут Флорида (Us)
Publication of RU2010101093A publication Critical patent/RU2010101093A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2010101093/10A 2007-06-15 2008-06-13 Способы диагностики и лечения рака RU2010101093A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US94415707P 2007-06-15 2007-06-15
US60/944,157 2007-06-15
US3955508P 2008-03-26 2008-03-26
US61/039,555 2008-03-26

Publications (1)

Publication Number Publication Date
RU2010101093A true RU2010101093A (ru) 2011-07-20

Family

ID=40156627

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010101093/10A RU2010101093A (ru) 2007-06-15 2008-06-13 Способы диагностики и лечения рака

Country Status (12)

Country Link
US (1) US20090017012A1 (enExample)
EP (1) EP2171086B1 (enExample)
JP (1) JP5479332B2 (enExample)
KR (1) KR20100044780A (enExample)
CN (1) CN101815793A (enExample)
AU (1) AU2008266048A1 (enExample)
BR (1) BRPI0813364A2 (enExample)
CA (1) CA2690865A1 (enExample)
ES (1) ES2401475T3 (enExample)
MX (1) MX2009013646A (enExample)
RU (1) RU2010101093A (enExample)
WO (1) WO2008157353A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008541701A (ja) * 2005-05-04 2008-11-27 ユニヴァーシティ オブ サウス フロリダ がんの対象における処置応答の予測
US8700335B2 (en) 2006-05-18 2014-04-15 Caris Mpi, Inc. System and method for determining individualized medical intervention for a disease state
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
EP2350320A4 (en) * 2008-11-12 2012-11-14 Caris Life Sciences Luxembourg Holdings METHOD AND SYSTEMS FOR USE OF EXOSOMES FOR THE DETERMINATION OF PHENOTYPES
JP5024736B2 (ja) 2009-10-15 2012-09-12 住友電気工業株式会社 発電システム
AU2011223789A1 (en) 2010-03-01 2012-09-20 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
KR20130028727A (ko) 2010-03-29 2013-03-19 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
US9393318B2 (en) * 2010-03-29 2016-07-19 Abraxis Bioscience, Llc Methods of treating cancer
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
KR101602532B1 (ko) * 2013-08-29 2016-03-11 경북대학교 산학협력단 위암의 재발 가능성 예측을 위한 정보제공 방법
JP6681475B2 (ja) * 2015-10-26 2020-04-15 サイフェローム がん患者のゲノム塩基配列変異情報と生存情報を利用したカスタマイズ型の薬物選択方法及びシステム
EP4178448A4 (en) * 2020-07-10 2025-06-18 Progenics Pharmaceuticals, Inc. Methods of making prostate cancer treatment decisions
CN113957145B (zh) * 2021-10-19 2023-09-26 中国医学科学院肿瘤医院 m6A相关lncRNA在预测小细胞肺癌预后和化疗反应的应用
CN114564622B (zh) * 2022-03-03 2025-07-25 苏州良医汇网络科技有限公司 一种tnm分期表录入系统的方法、装置以及设备

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705336A (en) * 1995-03-07 1998-01-06 The United States Of America As Represented By The Department Of Health And Human Services Assay for sensitivity of tumors to DNA-platinating chemotherapy
US20020090642A1 (en) * 1995-12-11 2002-07-11 Patrick G. Johnston Methods for determining the prognosis of breast cancer using antibodies specific for thymidylate synthase
WO1998033518A1 (en) * 1997-02-04 1998-08-06 Sloan-Kettering Institute For Cancer Research Mutants of thymidylate synthase and uses thereof
US6087489A (en) * 1998-06-02 2000-07-11 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of human thymidylate synthase expression
EP1191096B1 (en) * 1999-06-28 2011-10-12 Yusuke Nakamura Ovel protein and dna thereof
US6248535B1 (en) * 1999-12-20 2001-06-19 University Of Southern California Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens
US6602670B2 (en) * 2000-12-01 2003-08-05 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
US6582919B2 (en) * 2001-06-11 2003-06-24 Response Genetics, Inc. Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
US7049059B2 (en) * 2000-12-01 2006-05-23 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression
US6518416B1 (en) * 2000-12-01 2003-02-11 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
US6956111B2 (en) * 2001-03-02 2005-10-18 Response Genetics, Inc. Method of determining dihydropyrimidine dehydrogenase gene expression
US6686155B2 (en) * 2001-06-14 2004-02-03 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression
WO2004031408A1 (en) * 2002-09-30 2004-04-15 F.Hoffmann-La Roche Ag Oligonucleotides for genotyping thymidylate synthase gene
AU2004285103A1 (en) * 2003-09-29 2005-05-12 Pathwork Diagnostics, Inc. Systems and methods for detecting biological features
JP2008541701A (ja) * 2005-05-04 2008-11-27 ユニヴァーシティ オブ サウス フロリダ がんの対象における処置応答の予測

Also Published As

Publication number Publication date
US20090017012A1 (en) 2009-01-15
JP2010530746A (ja) 2010-09-16
ES2401475T3 (es) 2013-04-19
CN101815793A (zh) 2010-08-25
WO2008157353A1 (en) 2008-12-24
MX2009013646A (es) 2010-03-30
EP2171086A1 (en) 2010-04-07
EP2171086A4 (en) 2010-10-13
EP2171086B1 (en) 2012-12-19
CA2690865A1 (en) 2008-12-24
JP5479332B2 (ja) 2014-04-23
KR20100044780A (ko) 2010-04-30
AU2008266048A1 (en) 2008-12-24
BRPI0813364A2 (pt) 2014-12-30

Similar Documents

Publication Publication Date Title
US8198024B2 (en) Gene expression markers for colorectal cancer prognosis
ES2488845T5 (es) Predicción de la probabilidad de recidiva de cáncer
ES2741745T3 (es) Método para usar la expresión génica para determinar el pronóstico de cáncer de próstata
JP2010530746A5 (enExample)
US20090258795A1 (en) Gene expression markers for prediction of patient response to chemotherapy
US20090305277A1 (en) Gene expression markers for prediction of patient response to chemotherapy
Wu et al. Long noncoding RNA HOTTIP expression predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation
CN116042832A (zh) 一种预测非小细胞肺癌免疫治疗获益程度及预后的生物标志物及应用
CN116761899A (zh) 结直肠癌分子分型及生存风险基因群及诊断产品和应用
Zhang et al. Long non-coding RNA FEZF1-AS1 is up-regulated and associated with poor prognosis in patients with cervical cancer.
Chen et al. Highly expressed circ_0000285 from serum and cervical exfoliated cells as a novel biomarker for the diagnosis of early stage-cervical cancer
Laurenti et al. Comparison of ZAP-70/Syk mRNA levels with immunoglobulin heavy-chain gene mutation status and disease progression in chronic lymphocytic leukemia
CN118922561A (zh) 肾癌诊断用尿液miRNA标志物、诊断试剂及试剂盒
CN110257514A (zh) 一种新的食管癌血液miRNA标志物及其应用
CN115896290A (zh) Trim21基因检测在肿瘤诊断、治疗选择和预后评估中的应用
CN104630380B (zh) 碳酸酐酶iv在制备肺腺癌诊断制剂中的应用
CN121137157B (zh) 一种评估上皮性卵巢癌复发风险的试剂的用途
CN113957145A (zh) m6A相关lncRNA在预测小细胞肺癌预后和化疗反应的应用
Xu et al. Identification of an Excellent PCR-Based Classifier to Predict Tumor Relapse in Stage II/III Colorectal Cancer and Its Clinical Application Irrespective of Consensus Molecular Subtypes
CN112368399A (zh) miRNA用于高级别浆液性卵巢癌治疗护理的预测和预后用途
Wu et al. Preoperative Immune Cells Infiltration in the Tumor Microenvironment as a Prediction and Prognostic Factor for Postoperative Recurrence in Hepatocellular Carcinoma
Torrente-Rodríguez et al. Advanced electrochemical scaffolds for multiplexed biosensing of cancer reporters in complex clinical samples
HK1166350A (en) Gene expression markers for colorectal cancer prognosis
HK1167004A (en) Gene expression markers for colorectal cancer prognosis
HK1165507A (en) Gene expression markers for colorectal cancer prognosis

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20130128